A global Phase 3, open label, Randomized Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy vs the standard of care treatment in adult patients with high-risk, transplant-eligible Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma (ANTLER-Phase 3 [Part III])
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
Caribou Biosciences